SOURCE: Equity News Circuit

Equity News Circuit

April 03, 2013 08:45 ET

Free Research Reports on AET, EXM, HIMX and RPTP Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - Apr 3, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Aetna Inc. (NYSE: AET) shares increase 3.67 percent on more than three times the average daily volume Tuesday to close at $54.30 a share. Healthcare insurers were boosted by the Centers for Medicare and Medicaid Services decision to boost payments for private Medicare Advantage insurers by 3.3 percent.

Find out more about Aetna including full access to the free equity report at: www.BedfordReport.com/AET

Excel Maritime Carriers Ltd. (NYSE: EXM) shares declined 11.82 percent on volume of over 2.3 million shares traded Tuesday to close at $0.97 a share. For the full year 2012, the company reported voyage revenues of $242.0 million, compared to voyage revenues of $353.4 million posted one year ago.

Find out more about Excel Maritime Carriers including full access to the free equity report at: www.BedfordReport.com/EXM

Himax Technologies, Inc. (NASDAQ: HIMX) shares spiked 8.84 percent on volume of 7.60 million shares traded Tuesday to close at $5.54 a share. The company is expected to release results for the first quarter of 2013 on Monday, May 6th. For the fourth quarter of 2012, Himax reported a net income of $14.3 million, a 285.8 percent increase when compared to the year ago quarter.

Find out more about Himax Technologies including full access to the free equity report at: www.BedfordReport.com/HIMX

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares gained 7.71 percent on more than double the average daily volume Tuesday to close at $6.01 a share. The Company is currently focused on the development of its first product candidate, RP103, as a potential treatment for nephropathic cystinosis, a rare genetic disorder.

Find out more about Raptor Pharmaceutical including full access to the free equity report at: www.BedfordReport.com/RPTP

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information